Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1966
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 2
1971 1
1972 1
1974 1
1979 1
1980 4
1982 1
1983 1
1986 5
1987 2
1988 2
1989 1
1990 2
1991 5
1992 3
1993 4
1994 4
1995 10
1996 3
1997 8
1998 2
1999 10
2000 4
2001 6
2002 10
2003 6
2004 7
2005 7
2006 7
2007 6
2008 6
2009 10
2010 14
2011 5
2012 11
2013 12
2014 5
2015 9
2016 13
2017 24
2018 8
2019 5
2020 3
2021 15
2022 19
2023 20
2024 16
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

296 results

Results by year

Filters applied: . Clear all
Page 1
Cardiomyopathy: An Overview.
Brieler J, Breeden MA, Tucker J. Brieler J, et al. Am Fam Physician. 2017 Nov 15;96(10):640-646. Am Fam Physician. 2017. PMID: 29431384 Free article. Review.
The definition and classification of cardiomyopathy have evolved considerably in recent years. Cardiomyopathy can be separated into primary (genetic, mixed, or acquired) and secondary categories, which result in varied phenotypes including dilated, hypertrophic
The definition and classification of cardiomyopathy have evolved considerably in recent years. Cardiomyopathy can be separated …
Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ismayl M, Abbasi MA, Marar R, Geske JB, Gersh BJ, Anavekar NS. Ismayl M, et al. Curr Probl Cardiol. 2023 Jan;48(1):101429. doi: 10.1016/j.cpcardiol.2022.101429. Epub 2022 Sep 24. Curr Probl Cardiol. 2023. PMID: 36167226 Review.
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, yet pharmacological therapy has been unchanged for decades until the recent introduction of mavacamten, a first-in-class cardiac myosin inhibitor. ...Compared to placebo, mavacamte
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, yet pharmacological therapy has been unc
Pheochromocytoma/paraganglioma-associated cardiomyopathy.
Szatko A, Glinicki P, Gietka-Czernel M. Szatko A, et al. Front Endocrinol (Lausanne). 2023 Jul 13;14:1204851. doi: 10.3389/fendo.2023.1204851. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37522121 Free PMC article. Review.
Catecholamine excess can manifest in several cardiovascular syndromes, including cardiomyopathy. PPGL-induced cardiomyopathies occur in up to 11% of cases and are most often associated with an adrenal pheochromocytoma (90%) and rarely with a paraganglioma derived from the …
Catecholamine excess can manifest in several cardiovascular syndromes, including cardiomyopathy. PPGL-induced cardiomyopathies occur …
A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy.
Yacoub MS, El-Nakhal T, Hasabo EA, Shehata N, Wilson K, Ismail KH, Bakr MS, Mohsen M, Mohamed A, Abdelazim E, Ali HT, Soliman Z, Sayed A, Abdelsayed K, Caliskan K, Soliman O. Yacoub MS, et al. Heart Fail Rev. 2024 Mar;29(2):479-496. doi: 10.1007/s10741-023-10375-6. Epub 2023 Dec 19. Heart Fail Rev. 2024. PMID: 38112937 Review.
Hypertrophic cardiomyopathy (HCM) is the most common heritable myocardial disorder worldwide. ...Mavacamten showed a statistically significant increase in the frequency of the primary composite endpoint (RR = 1.92, 95% CI [1.28, 2.88]), 1 NYHA class improvement (RR
Hypertrophic cardiomyopathy (HCM) is the most common heritable myocardial disorder worldwide. ...Mavacamten showed a statistic
Hypertrophic cardiomyopathy: a systematic review.
Maron BJ. Maron BJ. JAMA. 2002 Mar 13;287(10):1308-20. doi: 10.1001/jama.287.10.1308. JAMA. 2002. PMID: 11886323 Review.
CONTEXT: Throughout the past 40 years, a vast and sometimes contradictory literature has accumulated regarding hypertrophic cardiomyopathy (HCM), a genetic cardiac disease caused by a variety of mutations in genes encoding sarcomeric proteins and characterized by a …
CONTEXT: Throughout the past 40 years, a vast and sometimes contradictory literature has accumulated regarding hypertrophic cardio
Accurate Classification of Non-ischemic Cardiomyopathy.
Wang Y, Jia H, Song J. Wang Y, et al. Curr Cardiol Rep. 2023 Oct;25(10):1299-1317. doi: 10.1007/s11886-023-01944-0. Epub 2023 Sep 15. Curr Cardiol Rep. 2023. PMID: 37721634 Free PMC article. Review.
RECENT FINDINGS: Non-ischemic cardiomyopathy refers to a myocardial disease that excludes coronary artery disease or ischemic injury and has a variety of etiologies and high incidence. ...This article systematically describes the history of classifications of cardiomyop
RECENT FINDINGS: Non-ischemic cardiomyopathy refers to a myocardial disease that excludes coronary artery disease or ischemic injury …
Mavacamten: First Approval.
Keam SJ. Keam SJ. Drugs. 2022 Jul;82(10):1127-1135. doi: 10.1007/s40265-022-01739-7. Epub 2022 Jul 8. Drugs. 2022. PMID: 35802255 Free PMC article. Review.
Mavacamten (Camzyos) is an oral small-molecule cardiac myosin inhibitor developed by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of diastolic dysfunction. In April 2022, mava …
Mavacamten (Camzyos) is an oral small-molecule cardiac myosin inhibitor developed by MyoKardia, Inc., a wholly owned subsidiary of Bristol M …
Recent successes in heart failure treatment.
Lam CSP, Docherty KF, Ho JE, McMurray JJV, Myhre PL, Omland T. Lam CSP, et al. Nat Med. 2023 Oct;29(10):2424-2437. doi: 10.1038/s41591-023-02567-2. Epub 2023 Oct 9. Nat Med. 2023. PMID: 37814060 Review.
Great strides have been taken in the treatment of specific cardiomyopathies such as cardiac amyloidosis and hypertrophic cardiomyopathy, whereby conditions once considered incurable can now be effectively managed with novel genetic and molecular approaches. ...
Great strides have been taken in the treatment of specific cardiomyopathies such as cardiac amyloidosis and hypertrophic cardiomyo
Dilated cardiomyopathy: the complexity of a diverse genetic architecture.
Hershberger RE, Hedges DJ, Morales A. Hershberger RE, et al. Nat Rev Cardiol. 2013 Sep;10(9):531-47. doi: 10.1038/nrcardio.2013.105. Epub 2013 Jul 30. Nat Rev Cardiol. 2013. PMID: 23900355 Review.
Remarkable progress has been made in understanding the genetic basis of dilated cardiomyopathy (DCM). Rare variants in >30 genes, some also involved in other cardiomyopathies, muscular dystrophy, or syndromic disease, perturb a diverse set of important myocardial protei …
Remarkable progress has been made in understanding the genetic basis of dilated cardiomyopathy (DCM). Rare variants in >30 genes, …
296 results